This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations.

This guideline was funded by Camurus Ltd. The funding enabled SMMGP to provide clinical, managerial, editorial and administrative input.

Please click here to download the full document.

Please click here to download the executive summary.